In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to balance access, innovation and cost control. But the same cannot be said for patients in other countries. In fact, a new analysis from Avalere underscores the dangers of the Most Favored Nation (MFN) rule and other foreign reference pricing proposals.